[{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Not Applicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Series B Financing","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Compass Pathways \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Not Applicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Not Applicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"MiHKAL GmbH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Psychedelic Compound","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Compass Pathways \/ MiHKAL GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Compass Pathways \/ MiHKAL GmbH"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Not Applicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Not Applicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Not Applicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Not Applicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Not Applicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"The Centre for Mental Health Research and Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Compass Pathways \/ The Centre for Mental Health Research and Innovation","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ The Centre for Mental Health Research and Innovation"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Not Applicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Compass Pathways","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Compass Pathways \/ COMPASS Pathways","highestDevelopmentStatusID":"4","companyTruncated":"Compass Pathways \/ COMPASS Pathways"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Not Applicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Kings College London","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Compass Pathways \/ King\u2019s College London","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ King\u2019s College London"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Not Applicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Not Applicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Compass Pathways \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Hercules Capital"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.28999999999999998,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ TCGX"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Not Applicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Greenbrook TMS","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Greenbrook TMS","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Greenbrook TMS"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Hackensack Meridian Health","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Hackensack Meridian Health"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Not Applicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Journey Clinical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Journey Clinical","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Journey Clinical"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Mindful Health Solutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Mindful Health Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Mindful Health Solutions"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Compass Pathways

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : COMP360 (psilocybin) treatment is currently being evaluated in phase 2 clinical trials for the treatment of patients with post-traumatic stress disorder (PTSD).

                          Brand Name : COMP360

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 08, 2024

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The research collaboration agreement aims to aid in the development and establishment of a cost-effective delivery model for COMP360 (psilocybin) for treating treatment-resistant depression.

                          Brand Name : COMP360

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 02, 2024

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Mindful Health Solutions

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The collaboration aims to support the clinical development of COMP360 (psilocybin), which is currently undergoing late-stage clinical trial evaluation for treatment-resistant depression.

                          Brand Name : COMP360

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 29, 2024

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Journey Clinical

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The collaboration aims to inform the delivery model design of investigational COMP360, a proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD).

                          Brand Name : COMP360

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 16, 2024

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Hackensack Meridian Health

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The collaboration aims to explore delivery models for investigational COMP360 psilocybin treatment upon regulatory approval by the U.S. Food and Drug Administration.

                          Brand Name : COMP360

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 05, 2024

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Greenbrook TMS

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : COMP360 (psilocybin) treatment is currently being evaluated in phase 2 clinical trials for the treatment of patients with post-traumatic stress disorder (PTSD).

                          Brand Name : COMP360

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 19, 2023

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : COMP360 psilocybin therapy to help people with treatment-resistant depression (TRD), post-traumatic stress disorder and anorexia nervosa. The phase 3 program consists of two pivotal trials (COMP 005 and COMP 006), and each trial has an integrated, long-t...

                          Brand Name : COMP360

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 15, 2023

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The net proceeds will be used to advance the pivotal phase 3 program for COMP360 psilocybin therapy to help people with treatment-resistant depression (TRD), post-traumatic stress disorder and anorexia nervosa.

                          Brand Name : COMP360

                          Molecule Type : Small molecule

                          Upfront Cash : $125.0 million

                          August 16, 2023

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : TCGX

                          Deal Size : $285.0 million

                          Deal Type : Private Placement

                          blank

                          09

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The net financing will support company's COMP360, a stabilised, high-purity polymorphic crystalline synthesised formulation of psilocybin, in phase 3 program in treatment-resistant depression (TRD).

                          Brand Name : COMP360

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 05, 2023

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Hercules Capital

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          10

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : COMP360 is stabilised, high-purity polymorphic crystalline synthesised formulation of psilocybin, act on serotonin 2a receptor in brain, believed that acting on this receptor may make brain work with greater flexibility, allowing region to connect and co...

                          Brand Name : COMP360

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 02, 2022

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank